Ditchcarbon
  • Customers
  1. Organizations
  2. Argenx
Public Profile
Pharmaceutical Preparation Manufacturing
NL
updated a month ago

Argenx

Company website

Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.

DitchCarbon Score

How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Argenx's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

56%

Let us know if this data was useful to you

Argenx's reported carbon emissions

In 2023, Argenx reported total carbon emissions of approximately 433,353,000 kg CO2e. This figure includes Scope 1 emissions of about 378,000 kg CO2e and Scope 2 emissions of approximately 189,000 kg CO2e (market-based). The majority of their emissions, around 432,786,000 kg CO2e, fall under Scope 3, which encompasses various categories such as purchased goods and services (approximately 378,956,000 kg CO2e) and business travel (about 5,328,000 kg CO2e). As of 2024, no new emissions data has been disclosed, and there are currently no specific reduction targets or climate pledges outlined by Argenx. The company has not cascaded any emissions data from a parent organisation, indicating that all reported figures are directly from Argenx SE. Argenx's commitment to addressing climate change is evident through their transparency in emissions reporting, although further details on reduction initiatives or targets are not available at this time.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2023
Scope 1
378,000
Scope 2
189,000
Scope 3
432,786,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Argenx's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Argenx is in NL, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Argenx is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Zealand Pharma A/S

DK
•
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 1 hour ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
dev
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy